Q2 EPS Estimates for Aurora Cannabis Cut by Atb Cap Markets

Key Points

• ATB Capital Markets has revised its Q2 2026 earnings per share estimate for Aurora Cannabis from ($0.06) to ($0.07), indicating a more pessimistic outlook for the company.
• Aurora Cannabis reported disappointing earnings for the last quarter, with a loss of ($0.19) EPS compared to the expected gain of $0.18, and revenue of $71.98 million falling short of estimates.
• Wall Street Zen downgraded Aurora Cannabis shares from a "hold" rating to a "sell" rating, reflecting growing concerns over the company's financial performance.

Aurora Cannabis Inc. (NASDAQ:ACB - Free Report) - Investment analysts at Atb Cap Markets lowered their Q2 2026 earnings estimates for Aurora Cannabis in a research note issued on Wednesday, August 6th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings per share of ($0.07) for the quarter, down from their prior estimate of ($0.06). The consensus estimate for Aurora Cannabis' current full-year earnings is $0.46 per share. Atb Cap Markets also issued estimates for Aurora Cannabis' Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at $0.15 EPS and FY2029 earnings at $0.30 EPS.

Separately, Wall Street Zen lowered shares of Aurora Cannabis from a "hold" rating to a "sell" rating in a report on Friday, July 18th.

Aurora Cannabis Price Performance

Shares of Aurora Cannabis stock opened at $4.48 on Monday. Aurora Cannabis has a twelve month low of $3.42 and a twelve month high of $7.20. The company has a quick ratio of 1.51, a current ratio of 2.97 and a debt-to-equity ratio of 0.06. The company has a 50-day simple moving average of $4.79 and a two-hundred day simple moving average of $4.80. The stock has a market capitalization of $252.90 million, a price-to-earnings ratio of -23.58 and a beta of 1.84.

Aurora Cannabis (NASDAQ:ACB - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.37). The company had revenue of $71.98 million for the quarter, compared to analyst estimates of $96.83 million. Aurora Cannabis had a negative return on equity of 1.49% and a negative net margin of 5.66%.

Institutional Investors Weigh In On Aurora Cannabis

Several hedge funds have recently added to or reduced their stakes in ACB. Renaissance Technologies LLC boosted its position in Aurora Cannabis by 8.6% during the 4th quarter. Renaissance Technologies LLC now owns 714,655 shares of the company's stock worth $3,037,000 after buying an additional 56,400 shares during the period. Dimensional Fund Advisors LP boosted its position in Aurora Cannabis by 7.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 84,921 shares of the company's stock worth $361,000 after buying an additional 5,800 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in Aurora Cannabis during the 4th quarter worth approximately $45,000. Bulltick Wealth Management LLC acquired a new stake in Aurora Cannabis during the 4th quarter worth approximately $150,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Aurora Cannabis during the 4th quarter worth approximately $221,000. 47.63% of the stock is currently owned by institutional investors and hedge funds.

Aurora Cannabis Company Profile

Aurora Cannabis Inc, together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.